<DOC>
	<DOCNO>NCT00927147</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety boron neutron capture therapy ( BNCT ) administer combination cetuximab treatment head neck cancer recur locally follow conventional cancer treatment ( surgery radiation therapy ) . Boron neutron capture therapy special form radiation therapy , base interaction boron atom take cancerous tissue neutron irradiation . The boron atom , locate within cancer cell , may capture low-energy neutron obtain nuclear accelerator , result split ( fission ) boron atom , high radiation effect within tumor . Cetuximab antibody direct certain protein find cancer cell surface ( epidermal growth factor receptor ) . When administer immediately BNCT , cetuximab may may improve treatment efficacy .</brief_summary>
	<brief_title>Boron Neutron Capture Therapy ( BNCT ) Combined With Cetuximab Treatment Locally Recurred Head Neck Cancer</brief_title>
	<detailed_description>This single-center , non-randomized , non-comparative , open-label , phase I/II trial determine safety efficacy BNCT treatment nonoperable , irradiated , locally advance cancer head neck region . Patients treat single-fraction boronophenylalanine ( BPA ) -based BNCT . All patient evaluate response use CT magnetic resonance imaging ( MRI ) . Neutron irradiation first plan base available tumor image examination , follow head body position determine irradiation , head fixation prepare test . On irradiation day 400 mg/m2 L-BPA-F infuse intravenously 2 hour . Cetuximab dose administer follow completion BNCT . The cetuximab dose escalate cohort 3 patient .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Boron</mesh_term>
	<criteria>Histologically confirm invasive squamous cell carcinoma head neck Inoperable tumor patient candidate surgery medical reason ; prior surgery may may do Prior radiotherapy chemoradiotherapy give tumor If prior 18Fboronophenylalanine ( BPA ) PET ( positron emission tomography ) do , BPA need accumulate least 2 time tumor correspond normal tissue A write informed consent Presence distant metastases A nonexperimental , effective treatment option available WHO performance status &gt; 3 WBC &lt; 2,500/mm3 , platelet &lt; 75,000/mm3 , serum creatinine &gt; 180 umol/L Concomitant systemic cancer chemotherapy ( except cetuximab ) . Other concurrent experimental therapy Less 1 month since prior radiation therapy Untreated severe treat congestive heart failure renal failure A cardiac pacemaker unremovable metal implant present head neck region interfere MRIbased doseplanning Restlessness inability lie cast 30 60 minute Clinical followup therapy arrange patient willing participate followup Pregnancy Age less 18 Known allergy/hypersensitivity cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>boron neutron capture therapy</keyword>
	<keyword>cetuximab</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>survival</keyword>
</DOC>